secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001104659-26-033724
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen reports 31% reduction in GA lesion growth at 12 months in Phase 2 OCU410 trial; plans Phase 3 in Q3 2026
--------------------------------------------------------------------------------

- 31% reduction in GA lesion growth (medium dose) vs control at 12 months (p<0.05); 55% of treated patients had ≥30% lesion reduction.
- No OCU410-related serious adverse events; no endophthalmitis, retinal detachment, or vasculitis reported.
- 27% slower rate of ellipsoid zone loss vs control, indicating photoreceptor preservation.
- Phase 3 pivotal trial with up to 300 subjects, adaptive design >95% power, expected to start Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926033724/0001104659-26-033724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926033724/tm269664d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-033724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer